Published in Am J Gastroenterol on July 01, 2004
Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis | NCT02438410
Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound | NCT01852760
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2010) 3.32
Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis (2009) 3.32
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol (2008) 2.41
Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci (2012) 1.93
Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol (2009) 1.80
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut (2008) 1.75
Gut microbiota and inflammation. Nutrients (2011) 1.60
Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis. Dig Dis Sci (2013) 1.48
Effect of follow-up endoscopy on the outcomes of patients with inflammatory bowel disease. Dig Dis Sci (2014) 1.48
A Case of In-Bore Transperineal MRI-Guided Prostate Biopsy of a Patient with Ileal Pouch-Anal Anastomosis. Case Rep Urol (2015) 1.39
Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci (2008) 1.38
Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.33
Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol (2008) 1.30
Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease. World J Gastroenterol (2013) 1.28
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol (2007) 1.28
Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica (2009) 1.23
Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res (2011) 1.21
Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip. Mol Cell Proteomics (2009) 1.14
The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag (2007) 1.12
Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. Dig Dis Sci (2008) 1.10
Self-management for people with inflammatory bowel disease. Can J Gastroenterol (2008) 1.09
Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol (2008) 1.08
New serological biomarkers of inflammatory bowel disease. World J Gastroenterol (2008) 1.06
Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol (2014) 1.01
Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis (2010) 1.00
Quality improvement in inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2013) 1.00
Ulcerative colitis-associated colorectal cancer. World J Gastroenterol (2014) 0.97
Colon cancer screening and surveillance in inflammatory bowel disease. Clin Endosc (2014) 0.95
Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol (2015) 0.95
Low body mass index can identify majority of osteoporotic inflammatory bowel disease patients missed by current guidelines. ScientificWorldJournal (2012) 0.95
Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Dig Dis Sci (2010) 0.95
Inflammatory Bowel Disease-related Colorectal Cancer in the Asia-Pacific Region: Past, Present, and Future. Intest Res (2014) 0.93
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis (2010) 0.93
Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment. Gut (2006) 0.91
Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol (2009) 0.91
An overview of lipid abnormalities in patients with inflammatory bowel disease. Ann Gastroenterol (2011) 0.90
Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis (2010) 0.90
Surveillance of dysplasia in inflammatory bowel disease: The gastroenterologist-pathologist partnership. Clin Gastroenterol Hepatol (2006) 0.90
Atypical distribution of inflammation in newly diagnosed ulcerative colitis is not rare. Can J Gastroenterol Hepatol (2014) 0.90
Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis (2010) 0.89
Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. J Gastroenterol (2010) 0.89
Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn's colitis patients in the Netherlands. World J Gastroenterol (2009) 0.88
Minilaparoscopy-assisted natural orifice total colectomy: technical report of a minilaparoscopy-assisted transrectal resection. Surg Endosc (2012) 0.87
Laparoscopic subtotal colectomy for medically refractory ulcerative colitis: the time has come. Surg Endosc (2010) 0.87
New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. Eur J Clin Pharmacol (2007) 0.87
A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis. Colorectal Dis (2008) 0.87
Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial. Clin Exp Gastroenterol (2013) 0.87
Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci (2009) 0.86
Histological healing in inflammatory bowel disease: a still unfulfilled promise. World J Gastroenterol (2013) 0.86
Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease. Dig Dis Sci (2015) 0.85
Colorectal cancer surveillance in patients with inflammatory bowel disease: What is new? World J Gastrointest Endosc (2012) 0.85
Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci (2009) 0.84
Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. PLoS Curr (2011) 0.83
Diverticular disease: A therapeutic overview. World J Gastrointest Pharmacol Ther (2010) 0.83
Usefulness of Measuring Serum Procalcitonin Levels in Patients with Inflammatory Bowel Disease. Gut Liver (2016) 0.83
Animal models to study acute and chronic intestinal inflammation in mammals. Gut Pathog (2015) 0.83
Second Korean guidelines for the management of ulcerative colitis. Intest Res (2017) 0.83
MEFV gene mutations and its impact on the clinical course in ulcerative colitis patients. Rheumatol Int (2010) 0.83
Impact of inflammatory bowel disease on Japanese patients' quality of life: results of a patient questionnaire survey. J Gastroenterol (2016) 0.82
Cytomegalovirus-induced Hemorrhagic Colitis in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy. Clin Med Insights Case Rep (2015) 0.82
Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes. Gastroenterol Hepatol (N Y) (2009) 0.81
Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. J Pediatr Gastroenterol Nutr (2009) 0.81
A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis. Eur J Clin Pharmacol (2011) 0.81
Addressing Costs and Continuity of Care through Innovative Solutions for Infused Therapies: A Collaborative Experience with Infliximab. Am Health Drug Benefits (2011) 0.81
Refractory pancolitis: a novel presentation of idiopathic myointimal hyperplasia of mesenteric veins. Gastroenterol Hepatol (N Y) (2012) 0.81
Oral Manifestations of Crohn's Disease: A Case Report and Review of the Literature. Case Rep Dent (2015) 0.80
Refractory ulcerative colitis treatment. Gastroenterol Hepatol (N Y) (2007) 0.80
Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. Clin Exp Gastroenterol (2009) 0.80
Menstrual cycle changes in women with inflammatory bowel disease: a study from the ocean state Crohn's and colitis area registry. Inflamm Bowel Dis (2014) 0.80
Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study. Intest Res (2016) 0.79
Potential dual immunomodulatory role of VEGF in ulcerative colitis and colorectal carcinoma. Int J Med Sci (2014) 0.79
Inflammatory bowel disease. Middle East J Dig Dis (2012) 0.79
Renal and Gastrointestinal Considerations in Joint Replacement Surgery. J Nat Sci (2015) 0.79
Chromoendoscopy and Advanced Imaging Technologies for Surveillance of Patients with IBD. Gastroenterol Hepatol (N Y) (2012) 0.79
Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol (2010) 0.79
Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis. World J Gastroenterol (2008) 0.77
Recent advances in the management of distal ulcerative colitis. World J Gastrointest Pharmacol Ther (2010) 0.77
Quality of health care in the United States: implications for pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2009) 0.77
Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.77
Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol (2008) 0.77
Health-related quality of life in Chinese patients with mild and moderately active ulcerative colitis. PLoS One (2015) 0.77
Colorectal neoplasia in IBD--a single-center analysis of patients undergoing proctocolectomy. Int J Colorectal Dis (2015) 0.76
Gene expression profiles in peripheral blood mononuclear cells of ulcerative colitis patients. World J Gastroenterol (2013) 0.76
Histological healing after infliximab induction therapy in children with ulcerative colitis. World J Gastroenterol (2015) 0.76
Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther (2013) 0.76
5-ASA Dose-Response: Maximizing Efficacy and Adherence. Gastroenterol Hepatol (N Y) (2010) 0.76
A 3D Polymer Model for Future Nutrition Design Novel Nutrition Approach for Cystic Fibrosis, Ulcerative Colitis and Crohn's Disease. J Nanomedine Biotherapeutic Discov (2014) 0.76
Colorectal Cancer in Inflammatory Bowel Disease: Epidemiology, Pathogenesis and Surveillance. Gastrointest Tumors (2014) 0.76
Overcoming adherence issues in ulcerative colitis. Gastroenterol Hepatol (N Y) (2007) 0.76
Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. World J Gastroenterol (2015) 0.76
The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn's disease. Prz Gastroenterol (2016) 0.75
The Correlation of Serum IL-12B Expression With Disease Activity in Patients With Inflammatory Bowel Disease. Medicine (Baltimore) (2016) 0.75
Pulmonary function tests in ulcerative colitis. J Res Med Sci (2014) 0.75
Advanced endoscopic imaging for surveillance for dysplasia and colorectal cancer in inflammatory bowel disease: could the pathologist be further helped? Saudi J Gastroenterol (2014) 0.75
Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab. Ther Clin Risk Manag (2013) 0.75
Management of inflammatory bowel diseases in Eastern Europe. Postgrad Med J (2006) 0.75
Coordinated Hospital-Home Fecal Microbiota Transplantation via Percutaneous Endoscopic Cecostomy for Recurrent Steroid-Dependent Ulcerative Colitis. Gut Liver (2016) 0.75
Anti-cyclic citrullinated peptide antibodies in ulcerative colitis, and its relation with disease activity. Med J Islam Repub Iran (2014) 0.75
British Society of Gastroenterology guidelines for ulcerative colitis surveillance: creating consensus or confusion? Gut (2006) 0.75
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (2007) 9.44
Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol (2008) 7.94
American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol (2007) 7.49
Practice guidelines in acute pancreatitis. Am J Gastroenterol (2006) 7.05
Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (2010) 5.20
Alcoholic liver disease. Hepatology (2010) 5.04
Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol (2002) 3.94
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol (2014) 3.43
Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol (2009) 2.73
Guidelines for the management of dyspepsia. Am J Gastroenterol (2005) 2.39
Hepatic Encephalopathy. Am J Gastroenterol (2001) 2.37
Management of Crohn's disease in adults. Am J Gastroenterol (2001) 2.09
ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol (2007) 1.98
Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol (2004) 1.50
Bacterial-metal interactions: the potential role of aluminum and other trace elements in the etiology of Crohn's disease. Inflamm Bowel Dis (2004) 1.42
Is there physician bias against eliciting affective qualities of pain? J Clin Gastroenterol (2010) 1.40
A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol (2013) 0.96
Small bowel adenocarcinoma in Crohn's disease. J Gastrointest Surg (2011) 0.96
Adenocarcinoma following ileal pouch-anal anastomosis for ulcerative colitis: review of 26 cases. Inflamm Bowel Dis (2009) 0.94
Colorectal carcinoma in indeterminate colitis. Inflamm Bowel Dis (2009) 0.94
Segmental colitis associated with diverticular disease and other IBD look-alikes. J Clin Gastroenterol (2006) 0.90
Granulomatous enterocolitis associated with Hermansky-Pudlak syndrome. Am J Gastroenterol (2006) 0.89
Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis (2011) 0.86
Genomics and phenomics in Crohn's disease. Gastroenterology (2002) 0.84
Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. Inflamm Bowel Dis (2013) 0.84
Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? Inflamm Bowel Dis (2005) 0.82
The myth of gastrointestinal sarcoidosis: a case of guilt by association. Inflamm Bowel Dis (2004) 0.79
Relationship of the number of Crohn's strictures and strictureplasties to postoperative recurrence. J Am Coll Surg (2009) 0.78
High rates of metachronous colon cancer or dysplasia after segmental resection or subtotal colectomy in Crohn's colitis. Inflamm Bowel Dis (2013) 0.76
Inflammation: an equal-opportunity process. Dig Dis Sci (2011) 0.75
6-mercaptopurine beats a bum rap. Gastroenterology (2003) 0.75
Filtering out the phagocytes in inflammatory bowel disease. J Clin Gastroenterol (2005) 0.75
Pulse steroids for ulcerative colitis: good news, bad news, and no news. J Clin Gastroenterol (2002) 0.75
Studying inflammatory bowel disease in the global laboratory. J Gastrointestin Liver Dis (2009) 0.75
Leflunomide in Crohn's disease--the open-label case series and the Texas sharpshooter. J Clin Gastroenterol (2003) 0.75
Ulcerative colitis: dead or alive. Ann Intern Med (2015) 0.75
Bleeding diathesis in amyloidosis with renal insufficiency associated with Crohn's disease: response to desmopressin. Am J Gastroenterol (2002) 0.75
Infliximab in Crohn's disease-associated toxic megacolon. J Clin Gastroenterol (2012) 0.75